share_log

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

In8Bio将出席诺布尔资本市场新兴增长虚拟医疗股票会议
In8bio ·  04/16 00:00

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18th at 12:30pm ET.

纽约,2024 年 4 月 16 日(GLOBE NEWSWIRE)— in8Bio, Inc. 纳斯达克股票代码:INAB)是一家开发创新伽玛-德尔塔T细胞疗法的临床阶段生物制药公司,今天宣布,首席执行官兼联合创始人William Ho将于4月18日星期四出席诺布尔资本市场的新兴增长虚拟医疗保健股票会议第四 美国东部时间下午 12:30。

The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience. Attendees interested in viewing the live presentation can register for this event here: Virtual Healthcare Equity Conference Registration.

正式演讲将以炉边风格的问答环节为特色,欢迎现场虚拟观众提问。有兴趣观看现场演示的与会者可以在此处注册此活动: 虚拟医疗保健股权会议注册

The IN8bio management team will also be hosting one-on-one meetings during the virtual event with registered, qualified investor attendees. Interested parties should contact their Noble representative to schedule a meeting.

In8bio管理团队还将在虚拟活动期间与注册的合格投资者举行一对一的会议。有关各方应联系其Noble代表以安排会议。

A video webcast of the presentation will be available following the event on the Company's website https://investors.in8bio.com/news-events/events-presentations, and as part of a complete catalog of presentations available on Channelchek www.channelchek.com, the investor portal created by Noble. The webcast will be archived on the company's website and on Channelchek.com for 90 days following the event.

活动结束后,将在公司网站上提供该演讲的网络视频直播 https://investors.in8bio.com/news-events/events-presentations,也作为 Channelchek 上提供的完整演示文稿目录的一部分 wwwchannelchek.com,由诺布尔创建的投资者门户网站。网络直播将在活动结束后的90天内在公司网站和ChannelChek.com上存档。

About IN8bio

关于 in8Bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.

in8bio是一家临床阶段的生物制药公司,为癌症患者开发基于伽玛-德尔塔T细胞的免疫疗法。gamma-delta T 细胞是一组特殊的 T 细胞,具有独特的特性,包括区分健康组织和病变组织的能力。该公司的牵头项目 INB-400 正在进行多形性胶质母细胞瘤(GBM)的二期试验。其他项目包括实体肿瘤和血液学肿瘤的 1 期试验,包括针对 GBM 的 INB-200 和针对接受移植的血液系统恶性肿瘤患者的 INB-100。有关in8bio的更多信息,请访问www.in8bio.com。

About Noble Capital Markets, Inc.

关于诺布尔资本市场有限公司

Noble Capital Markets ("Noble") is a research driven investment bank that has supported small & microcap companies since 1984. As a FINRA and SEC licensed broker dealer Noble provides institutional-quality equity research, merchant and investment banking, and order execution services. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the last decade. Noble launched www.channelchek.com in 2018 - an investor community dedicated exclusively to public small and micro-cap companies and their industries. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 6,000 public emerging growth companies are listed on the site, with growing content including research, webcasts, podcasts, and balanced news.

诺布尔资本市场(“Noble”)是一家以研究为导向的投资银行,自1984年以来一直为小型和微型股公司提供支持。作为FINRA和SEC的持牌经纪交易商,Noble提供机构质量的股票研究、商业和投资银行以及订单执行服务。2005年,诺布尔成立了NobleCon,该投资者会议在过去十年中取得了长足的发展。Noble 推出 wwwchannelchek.com 2018年——一个专门关注上市小型和微型股公司及其行业的投资者社区。Channelchek是第一家向公众提供机构质量研究的服务,无需订阅即可免费提供各个级别的研究。该网站上列出了6,000多家上市新兴成长型公司,内容不断增加,包括研究、网络广播、播客和平衡新闻。

Corporate Contact:
IN8bio, Inc.
Glenn Schulman, PharmD, MPH
203.494.7411
gdschulman@IN8bio.com

公司联系人:
in8Bio, Inc.
格伦·舒尔曼,药学博士,公共卫生硕士
203.494.7411
gdschulman@IN8bio.com

Investors
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com

投资者
梅鲁顾问
李 M. 斯特恩
lstern@meruadvisors.com

Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com

媒体联系人
金伯利哈
KKH 顾问
917.291.5744
kimberly.ha@kkhadvisors.com

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发